Camosunate Junior Tablets – For Children Aged 7 to 13 Years

Effective Treatment for Uncomplicated Malaria

Camosunate Junior is an antimalarial medication specifically formulated for children aged 7 to 13 years. It combines two potent active ingredients, Artesunate (100 mg) and Amodiaquine (300 mg), to effectively treat acute uncomplicated malaria, including strains resistant to multiple drugs.

Active Ingredients

• Artesunate: 100 mg per tablet

• Amodiaquine: 300 mg per tablet

Indications

• Treatment of Acute Uncomplicated Malaria: Effective against Plasmodium falciparum, including multi-drug-resistant strains.

Dosage and Administration

• Dosage: Administer one Artesunate tablet and one Amodiaquine tablet once daily for three consecutive days.

• Administration:

  1. With Food: To enhance absorption and reduce gastrointestinal discomfort, administer the tablets with food.

  2. Swallowing: Ensure the child swallows the tablets whole with a sufficient amount of water.

  3. Completion of Therapy: It is crucial to complete the full three-day course, even if symptoms improve earlier, to ensure the complete elimination of the malaria parasite.

Precautions

• Medical Supervision: Use under the guidance of a healthcare professional.

• Allergies: Do not use if the child has known hypersensitivity to Artesunate, Amodiaquine, or any other components of the medication.

• Liver and Kidney Function: Caution is advised in children with liver or kidney impairments; consult a healthcare provider before use.

• Side Effects: Common side effects may include nausea, vomiting, abdominal pain, or dizziness. Seek medical attention if severe reactions occur.

Storage

• Store in a cool, dry place away from direct sunlight.

• Keep out of reach of children.

Note: Always consult a healthcare professional before administering any medication to ensure it is appropriate for the child's health condition.

Camosunate Junior provides a reliable and effective solution for treating uncomplicated malaria in children, adhering to recommended artemisinin-based combination therapies.